The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 37, 2011, Pages 15201-15206

  Wang, Beatrice T ^a   Ducker, Gregory S ^b   Barczak, Andrea J ^c   Barbeau, Rebecca ^c   Erle, David J ^c   Shokat, Kevan M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 Hydroxy 3 methylglutaryl CoA reductase; eIF4E binding protein 1 phosphorylation; Expression array; Sterol regulatory element binding protein 2; Thioredoxin interacting protein

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PP 242; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOMA CELL; CELL STRAIN 3T3; CHOLESTEROL SYNTHESIS; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HOMEOSTASIS; LIPID HOMEOSTASIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CHOLESTEROL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; LIVER NEOPLASMS; MICE; NIH 3T3 CELLS; PHOSPHOPROTEINS; PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

MAMMALIA;

EID: 80053083941     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1103746108     Document Type: Article

References (42)

1. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262.
2. Chiang GG, Abraham RT (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13:433-442. (Pubitemid 47570021)
3. Gustin JP, et al. (2009) Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci USA 106:2835-2840.
4. Lu ZH, et al. (2010) Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 70:3287-3298.
5. Murakami M, et al. (2004) mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 24:6710-6718. (Pubitemid 38944350)
6. Kim DH, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163-175.
7. Sarbassov DD, et al. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin- insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296-1302.
8. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945. (Pubitemid 39071573)
9. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101. (Pubitemid 40262113)
10. García-Martínez JM, Alessi DR (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416:375-385.
11. Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7:e38.
12. Thoreen CC, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284:8023-8032.
13. García-Martínez JM, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421:29-42.
14. Yu K, et al. (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69: 6232-6240.
15. Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332:1317-1322.
16. Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332:1322-1326.
17. Porstmann T, Santos CR, Lewis C, Griffiths B, Schulze A (2009) A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. Biochem Soc Trans 37:278-283.
18. Laplante M, Sabatini DM (2009) An emerging role of mTOR in lipid biosynthesis. Curr Biol 19:R1046-R1052.
19. Brown MS, Goldstein JL (1997) The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340. (Pubitemid 27220877)
20. Sato R, et al. (1996) Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2. J Biol Chem 271:26461-26464. (Pubitemid 26359040)
21. Porstmann T, et al. (2008) SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab 8:224-236.
22. Düvel K, et al. (2010) Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 39:171-183.
23. Luyimbazi D, et al. (2010) Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 9:2770-2784.
24. Porstmann T, et al. (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481. (Pubitemid 41486630)
25. Ma KL, et al. (2010) Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 298:H1646-H1651.
26. Gueguen Y, et al. (2007) Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol 100:392-397. (Pubitemid 46778677)
27. Sharpe LJ, Brown AJ (2008) Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 373:670-674.
28. Nakamura Y, Sakakibara J, Izumi T, Shibata A, Ono T (1996) Transcriptional regulation of squalene epoxidase by sterols and inhibitors in HeLa cells. J Biol Chem 271: 8053-8056. (Pubitemid 26108626)
29. Jacinto E, et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127:125-137. (Pubitemid 44466632)
30. Lewis CA, Griffiths B, Santos CR, Pende M, Schulze A (2010)) Genetic ablation of S6-kinase does not prevent processing of SREBP1. Adv Enzyme Regul 51:280-290.
31. Peng T, Golub TR, Sabatini DM (2002) The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 22:5575-5584. (Pubitemid 34755766)
32. Nishiyama A, et al. (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645-21650.
33. Hui ST, et al. (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA 105:3921-3926. (Pubitemid 351723500)
34. Kim SY, Suh HW, Chung JW, Yoon SR, Choi I (2007) Diverse functions of VDUP1 in cell proliferation, differentiation, and diseases. Cell Mol Immunol 4:345-351.
35. Jin HO, et al. (2011) TXNIP potentiates Redd1-induced mTOR suppression through stabilization of Redd1. Oncogene, 10.1038/onc.2011.102.
36. Han SH, et al. (2003) VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression. Oncogene 22: 4035-4046. (Pubitemid 36819644)
37. Bodnar JS, et al. (2002) Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet 30:110-116.
38. Komatsu M, Ruoslahti E (2005) R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 11:1346-1350. (Pubitemid 41752916)
39. Yoon KA, et al. (2006) Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer. Carcinogenesis 27:2217-2222.
40. Apsel B, et al. (2008) Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 4:691-699.
41. Anand NK, et al. (2005) Preparation and structure activity of pyrazolo-pyrimidine derivatives as antitumor agents and kinase modulators. WO2005117909.
42. Hsieh AC, et al. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17:249-261.